Clinical stage biopharmaceutical company Poxel, who focus on developing innovative treatments for chronic, serious diseases with metabolic pathophysiology, has been awarded Orphan Drug Designation (ODD) for two drugs for the treatment of adrenoleukodystrophy (ALD).
The FDA had previously granted OOD and Fast Track Designation for PXL770 and PXL065, with the EC’s decision coming after a positive indication from the Committee for Orphan Medicinal Products (COMP) of the European’s Medicines Agency (EMA).
